Hanlim wins 2nd trial for Allergan’s ‘Combigan’ composition patent, too
Hanlim Pharm, which filed the nullification trial of the glaucoma-treating ‘Combigan’ composition patent, won the 2nd trial, too, against Allergan owning the original product.
This winning has raise the chance for Hanlim Pharm to acquire the 9-month exclusive sale right of its generic from the n...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
